Document is current
Any future updates will be listed below
-
Authors
Juschten, Jenny http://orcid.org/0000-0003-2176-5072
,
Ingelse, Sarah A.
Bos, Lieuwe D. J.
Girbes, Armand R. J.
Juffermans, Nicole P.
van der Poll, Tom
Schultz, Marcus J.
Tuinman, Pieter Roel
-
Funding
Funding for this research was provided by:
ZonMw (114024057 (40-42600-98-702))
- License Information
-
More Information
Article History
Received: 22 July 2020
Accepted: 23 July 2020
First Online: 18 December 2020
Ethics approval and consent to participate
: Clinical study: The BASIC study was conducted according to the declaration of Helsinki, and the investigational protocol was approved by the local institutional review board (METC 2010_335#B201112) of the Amsterdam University Medical Centers, location “AMC,” the Netherlands. The study was registered at the Dutch Central Commission for Human bound Research (CCMO) (study identifier NL34294.018.10), and written informed consent was obtained from the participants and/or their representatives before any study-related action took place.Preclinical study: The experiment was conducted under protocols approved by the Animal Care and Use Committee of the Amsterdam University Medical Centers, location “AMC,” the Netherlands, (LEICA 132–AB and –AD).
: Not applicable.
: We declare that the tested recombinant alkaline phosphatase (recAP) was a kind gift from AM Pharma (Bunnik, The Netherlands). Except for this, the authors declare no other competing interests.
